Skip to main content

nuzefatide pevedotin

Generic: Nuzefatide Pevedotin·Code: BT5528

nuzefatide pevedotin: developed by 1 company · 3 clinical trials tracked.

nuzefatide pevedotin evidence translation

What we can confirm

What it means

Source-backed records connect nuzefatide pevedotin to BCYC; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could nuzefatide pevedotin → BCYC affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Related indications

advanced solid tumors and recurrent metastatic pancreatic ductal adenocarcinomaAdvanced Solid Tumor Historically Known for High EphA2 ExpressionAdvanced Solid TumorsHead and Neck CancerOvarian CancerPancreatic Ductal Adenocarcinoma (PDAC)Triple Negative Breast CancerUrothelial Cancer

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
BICYCLE THERAPEUTICS PLC (BCYC)
advanced solid tumors and recurrent metastatic pancreatic du…
Phase 2
BICYCLE THERAPEUTICS PLC (BCYC)
Advanced Solid Tumor Historically Known for High EphA2 Expre…
Phase 2
Clinical Trials (3)

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study

NCT07681674·Phase 2
Not yet recruiting

Primary endpoint: Monitor safety for participants receiving a Bicycle investigational product

Interventionalopen16 targetStarted 2026-08Completion 2030-05BicycleTx Limited

A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT07450859·Phase 2
Recruiting

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen39 targetStarted 2026-03Completion 2029-056 sites · United StatesBicycleTx Limited

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

NCT04180371·Phase 1·BCYC
Active, not recruiting

Primary endpoint: Part A-1 and A-2(escalations): Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse events

Interventionalopen288 targetStarted 2019-11Completion 2027-0728 sites · Belgium, South Korea, Spain, United Kingdom…BicycleTx Limited

Frequently asked questions

Who is developing nuzefatide pevedotin?

nuzefatide pevedotin is being developed by BICYCLE THERAPEUTICS PLC.

How many clinical trials involve nuzefatide pevedotin?

BioSniper tracks 3 clinical trials involving nuzefatide pevedotin.